Clinical studies have demonstrated that PD-1/PD-L1 inhibitors exhibit sustained response rates in the realm of lung cancer treatment and improve substantially the survival rates of advanced cancer patients by disrupting the PD-1/PD-L1 binding and relieving immune suppression. Here, CD274 is linked to lung carcinoma.